Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fUlvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Med Chem
Main Authors: Lu, Yunlong, Gutgesell, Lauren M., Xiong, Rui, Zhao, Jiong, Li, Yangfeng, Rosales, Carlo I., Hollas, Michael, Shen, Zhengnan, Gordon-Blake, Jesse, Dye, Katherine, Wang, Yueting, Lee, Sue, Chen, Hu, He, Donghong, Dubrovyskyii, Oleksii, Zhao, Huiping, Huang, Fei, Lasek, Amy W., Tonetti, Debra A., Thatcher, Gregory R. J.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7261373/
https://ncbi.nlm.nih.gov/pubmed/31746603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b01580
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki